FI3117216T3 - Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi - Google Patents
Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi Download PDFInfo
- Publication number
- FI3117216T3 FI3117216T3 FIEP15716168.8T FI15716168T FI3117216T3 FI 3117216 T3 FI3117216 T3 FI 3117216T3 FI 15716168 T FI15716168 T FI 15716168T FI 3117216 T3 FI3117216 T3 FI 3117216T3
- Authority
- FI
- Finland
- Prior art keywords
- solid tumor
- psa
- time point
- tumor cancer
- biomarker
- Prior art date
Links
Classifications
-
- G01N33/575—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G01N33/57555—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G01N33/57565—
-
- G01N33/5758—
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450274 | 2014-03-11 | ||
| SE1450420 | 2014-04-04 | ||
| PCT/SE2015/050272 WO2015137870A1 (en) | 2014-03-11 | 2015-03-11 | Method for detecting a solid tumor cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3117216T3 true FI3117216T3 (fi) | 2023-04-27 |
Family
ID=52829276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP15716168.8T FI3117216T3 (fi) | 2014-03-11 | 2015-03-11 | Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10451626B2 (enExample) |
| EP (2) | EP4220170A3 (enExample) |
| JP (1) | JP6625061B2 (enExample) |
| AU (2) | AU2015230017B2 (enExample) |
| CA (2) | CA2940445C (enExample) |
| DK (1) | DK3117216T3 (enExample) |
| FI (1) | FI3117216T3 (enExample) |
| RU (1) | RU2720148C9 (enExample) |
| WO (1) | WO2015137870A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013230167B2 (en) | 2012-03-05 | 2018-05-24 | Opko Diagnostics, Llc | Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| WO2015148979A1 (en) | 2014-03-28 | 2015-10-01 | Opko Diagnostics, Llc | Compositons and methods related to diagnosis of prostate cancer |
| JP6749337B2 (ja) | 2015-03-27 | 2020-09-02 | オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーＯｐｋｏ Ｄｉａｇｎｏｓｔｉｃｓ，Ｌｌｃ | 前立腺抗原標準およびその使用 |
| US11479878B2 (en) | 2016-03-16 | 2022-10-25 | Dana-Farber Cancer Institute, Inc. | Methods for genome characterization |
| ES2688213T3 (es) * | 2016-07-15 | 2018-10-31 | Proteomedix Ag | Método para detectar proteínas en muestras humanas y usos de dichos métodos |
| WO2018141828A1 (en) * | 2017-02-01 | 2018-08-09 | Phadia Ab | Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics |
| EP3577215A4 (en) * | 2017-02-03 | 2020-12-30 | The Johns Hopkins University | USE OF MINI-CANCERS FOR PERSONALIZED ANTI-CANCER DRUG PROTOCOLS |
| RU2664706C2 (ru) * | 2017-06-02 | 2018-08-21 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) | Способ прогнозирования клинического статуса рака предстательной железы |
| JP7127422B2 (ja) * | 2017-08-30 | 2022-08-30 | 東ソー株式会社 | 癌を検出する方法及び検出試薬 |
| WO2020205204A1 (en) * | 2019-04-03 | 2020-10-08 | Opko Diagnostics, Llc | Methods for the detection of prostate cancer |
| IT202000029948A1 (it) * | 2020-12-04 | 2022-06-04 | Nib Biotec S R L | Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età |
| WO2024092138A1 (en) * | 2022-10-27 | 2024-05-02 | Myome, Inc. | Approach for early detection of disease combining multiple data sources |
| WO2024092136A2 (en) * | 2022-10-28 | 2024-05-02 | Memorial Sloan-Kettering Cancer Center | Machine learning modeling for inpatient prediction |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030219840A1 (en) | 2002-05-24 | 2003-11-27 | Mikolajczyk Stephen D. | Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection |
| US20050277137A1 (en) | 2003-08-15 | 2005-12-15 | University Of Pittsburgh | Diagnostic multimarker serological profiling |
| KR100830811B1 (ko) * | 2006-09-18 | 2008-05-20 | 충북대학교 산학협력단 | 종양표시인자 검출용 바이오센서 |
| FR2934698B1 (fr) | 2008-08-01 | 2011-11-18 | Commissariat Energie Atomique | Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede. |
| WO2010081240A1 (en) | 2009-01-19 | 2010-07-22 | Miraculins Inc. | Diagnostic assays for prostate cancer using psp94 and psa biomarkers |
| WO2010093939A2 (en) | 2009-02-12 | 2010-08-19 | Dana-Farber Cancer Institute, Inc. | Predicting and treating prostate cancer |
| EP2407555A1 (en) | 2010-07-14 | 2012-01-18 | Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada | Methods and kits for the diagnosis of prostate cancer |
| WO2012031207A2 (en) | 2010-09-03 | 2012-03-08 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| US20120202888A1 (en) | 2010-10-08 | 2012-08-09 | The Brigham And Women's Hospital, Inc. | Biomarkers of prostate cancer and predicting mortality |
| US20120150032A1 (en) | 2010-12-13 | 2012-06-14 | Julius Gudmundsson | Sequence Variants Associated with Prostate Specific Antigen Levels |
| CA2823348A1 (en) | 2010-12-28 | 2012-07-05 | Caris Mpi, Inc. | Molecular profiling for cancer |
| CA2799163C (en) | 2011-12-18 | 2025-01-07 | 20/20 Genesystems, Inc. | METHODS AND ALGORITHMS TO AID IN CANCER DETECTION |
| CA2871877A1 (en) * | 2012-05-16 | 2013-11-21 | Phadia Ab | Method for indicating the presence or non-presence of prostate cancer |
| US10428385B2 (en) * | 2012-11-20 | 2019-10-01 | Phadia Ab | Prognostic method for individuals with prostate cancer |
| CA3092807C (en) | 2012-11-20 | 2024-02-27 | Phadia Ab | Method for indicating a presence or non-presence of aggressive prostate cancer |
-
2015
- 2015-03-11 AU AU2015230017A patent/AU2015230017B2/en active Active
- 2015-03-11 JP JP2016556777A patent/JP6625061B2/ja not_active Expired - Fee Related
- 2015-03-11 FI FIEP15716168.8T patent/FI3117216T3/fi active
- 2015-03-11 US US15/124,769 patent/US10451626B2/en active Active
- 2015-03-11 EP EP23150294.9A patent/EP4220170A3/en active Pending
- 2015-03-11 DK DK15716168.8T patent/DK3117216T3/da active
- 2015-03-11 RU RU2016139491A patent/RU2720148C9/ru active
- 2015-03-11 CA CA2940445A patent/CA2940445C/en active Active
- 2015-03-11 CA CA3134289A patent/CA3134289A1/en active Pending
- 2015-03-11 WO PCT/SE2015/050272 patent/WO2015137870A1/en not_active Ceased
- 2015-03-11 EP EP15716168.8A patent/EP3117216B1/en active Active
-
2021
- 2021-09-15 AU AU2021232712A patent/AU2021232712B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2720148C2 (ru) | 2020-04-24 |
| RU2016139491A (ru) | 2018-04-16 |
| AU2021232712B2 (en) | 2024-10-03 |
| CA3134289A1 (en) | 2015-09-17 |
| US10451626B2 (en) | 2019-10-22 |
| RU2720148C9 (ru) | 2020-09-28 |
| CA2940445C (en) | 2021-11-30 |
| RU2016139491A3 (enExample) | 2018-10-15 |
| US20170108501A1 (en) | 2017-04-20 |
| JP2017508970A (ja) | 2017-03-30 |
| JP6625061B2 (ja) | 2019-12-25 |
| HK1231559A1 (en) | 2017-12-22 |
| CA2940445A1 (en) | 2015-09-17 |
| EP4220170A2 (en) | 2023-08-02 |
| EP3117216A1 (en) | 2017-01-18 |
| AU2021232712A1 (en) | 2021-10-14 |
| AU2015230017B2 (en) | 2021-06-17 |
| DK3117216T3 (da) | 2023-04-03 |
| EP3117216B1 (en) | 2023-01-11 |
| AU2015230017A1 (en) | 2016-09-08 |
| EP4220170A3 (en) | 2023-12-13 |
| WO2015137870A1 (en) | 2015-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3117216T3 (fi) | Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi | |
| Brito-Rocha et al. | Shifting the cancer screening paradigm: the rising potential of blood-based multi-cancer early detection tests | |
| Chen et al. | Biomarkers for prostate cancer: from diagnosis to treatment | |
| JP2017508970A5 (enExample) | ||
| Kudela et al. | Breast cancer in young women: status quo and advanced disease management by a predictive, preventive, and personalized approach | |
| Markiewicz et al. | Spectrum of epithelial-mesenchymal transition phenotypes in circulating tumour cells from early breast cancer patients | |
| Han et al. | Liquid biopsy from bile-circulating tumor DNA in patients with biliary tract cancer | |
| Viëtor et al. | How to differentiate benign from malignant adrenocortical tumors? | |
| Martínez-Montiel et al. | Alternative splicing in breast cancer and the potential development of therapeutic tools | |
| Spans et al. | The genomic landscape of prostate cancer | |
| Kulbe et al. | Discovery and validation of novel biomarkers for detection of epithelial ovarian cancer | |
| JP2016508026A5 (enExample) | ||
| MX346031B (es) | Método para emplear expresión génica para determinar pronóstico de cáncer de próstata. | |
| Gezer et al. | The utility of repetitive cell-free DNA in cancer liquid biopsies | |
| Keup et al. | Combinatorial power of cfDNA, CTCs and EVs in oncology | |
| Adinew et al. | The prognostic and therapeutic implications of the chemoresistance gene BIRC5 in triple-negative breast cancer | |
| JP2016521979A5 (enExample) | ||
| Eickelschulte et al. | Biomarkers for the detection and risk stratification of aggressive prostate cancer | |
| Grizzi et al. | Circulating tumor DNA in gastric adenocarcinoma: future clinical applications and perspectives | |
| Wang et al. | Automatic detection of the circulating cell-free methylated DNA pattern of GCM2, ITPRIPL1 and CCDC181 for detection of early breast cancer and surgical treatment response | |
| Ravegnini et al. | Simultaneous analysis of SEPT9 promoter methylation status, micronuclei frequency, and folate-related gene polymorphisms: The potential for a novel blood-based colorectal cancer biomarker | |
| Meehan et al. | Tissue-and liquid-based biomarkers in prostate cancer precision medicine | |
| Borbiev et al. | Clinical biofluid assays for prostate cancer | |
| Huang et al. | The impact of matrix metalloproteinase-11 polymorphisms on colorectal cancer progression and clinicopathological characteristics | |
| Gao et al. | Proteomic tissue-based classifier for early prediction of prostate cancer progression |